Galectin Therapeutics reports FY2025 net loss $31M; belapectin data for EASL upcoming

GALECTIN THERAPEUTICS INC

Net loss $31.0M ($0.48/share) vs $47.2M ($0.76) in 2024; R&D expense down to $14.3M from $36.6M.
Cash $17.7M plus $10M credit line from chairman; runway through April 2027.
Belapectin NAVIGATE trial: varices incidence reduced 49.3% in per-protocol (p=0.04); U.S. subgroup 68.1% (p=0.02).
Additional biomarker data (FibroScan, ELF, PRO-C3) support antifibrotic activity; oral/poster presentations at EASL 2026.
Upcoming FDA meeting in Q2 2026 to align on next steps; no approved therapy for MASH cirrhosis.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GALECTIN THERAPEUTICS INC reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

GALECTIN THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001140361-26-012158

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.